(Q24630385)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Actions of ORG 5222 as a novel psychotropic agent

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Iloperidone for the treatment of schizophrenia

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Asenapine effects in animal models of psychosis and cognitive function

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

CNTRICS final task selection: control of attention

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Lessons to take home from CATIE.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Metabolic drug interactions with newer antipsychotics: a comparative review.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Cognitive Impairment and Functional Outcome in Schizophrenia and Bipolar Disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Suicide in schizophrenia.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Dopamine partial agonists: a new class of antipsychotic

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Animal behavior models of the mechanisms underlying antipsychotic atypicality

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Drug metabolism and atypical antipsychotics

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

What are the functional consequences of neurocognitive deficits in schizophrenia?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Asenapine versus olanzapine in acute mania: a double-blind extension study

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Behavioral pharmacology of olanzapine: a novel antipsychotic drug

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Prolongation of QTc interval and antipsychotics

30 May 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

Citation bias in reported smoking prevalence in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

Long-acting risperidone improves negative symptoms in stable psychotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

Dosing frequency and adherence to antipsychotic medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Memory and executive impairment in schizophrenia: comparison with frontal and temporal brain damage.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro- 1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924192

Physico-chemical properties and stability of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H- dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine maleate

28 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20642375

12 December 2020

inferred from PubMed ID database lookup

Risperidone for exclusively negative symptoms

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20642375

12 December 2020

inferred from PubMed ID database lookup

Risperidone Long-Acting Injection

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506188

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1517/14656566.2010.506188

1 reference

release_m2ncgsc6fzhexfklejn63hdlpy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m2ncgsc6fzhexfklejn63hdlpy

24 November 2022

mapped directly with Wikidata item

1 reference

1 reference

PubMed publication ID

20642375

1 reference